News
Heron Therapeutics
HRTX · NASDAQ
$0.3545−$0.0064 (−1.77%)TodayMarket closed ·
Prev close $0.3609
Latest news
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseGlobe Newswire
Heron Therapeutics Announces Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
- Press releaseGlobe Newswire
U.S. District Court Issues Decision Regarding CINVANTI® Patents
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseGlobe Newswire
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
- News
Earnings Scheduled For May 11, 2026
- Press releaseGlobe Newswire
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
- News
Earnings Breakdown: Heron Therapeutics Q4
- Press releaseGlobe Newswire
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
- News
Earnings Scheduled For February 26, 2026
- Press releaseGlobe Newswire
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
- Press releaseGlobe Newswire
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
- Press releaseGlobe Newswire
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
- Press releaseGlobe Newswire
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
- News
Earnings Scheduled For November 4, 2025
- Press releaseGlobe Newswire
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
- Press releaseGlobe Newswire
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
- Press releasePRNewswire
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releasePRNewswire
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
- Press releasePRNewswire
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
- Press releasePRNewswire
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
- Press releasePRNewswire
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
- Press releasePRNewswire
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
- Press releasePRNewswire
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
- Press releasePRNewswire
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
- Press releasePRNewswire
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
- Press releasePRNewswire
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
- Press releasePRNewswire
Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
- Press releasePRNewswire
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
- NewsAvi Kapoor
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
U.S. District Court Upholds Validity of CINVANTI® Patents
- NewsAvi Kapoor
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
- Press releasePRNewswire
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.